Li-Fraumeni Syndrome Clinical Trial
Official title:
Magnetic Resonance Imaging Screening In Li Fraumeni Syndrome: An Exploratory Whole Body MRI Study
This study is aimed at exploring the use of whole body MRI for early cancer detection in TP53 mutation carriers and population controls, with the hypothesis that more cancers will be detected in the TP53 mutation carrier group. A secondary end-point will be the number of incidental findings detected and subsequent investigations required. A series of questionnaires will be used to assess the psychological impact of screening on both the study and control group.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04367246 -
Li-Fraumeni Syndrome/TP53 Biobank
|
||
Recruiting |
NCT04541654 -
Li-Fraumeni & TP53 (LiFT UP): Understanding and Progress
|
||
Recruiting |
NCT05126810 -
Willingness to Participate in a Trial Comparing Standard Genetic Counseling Versus Personalized Genetic Counseling
|
||
Active, not recruiting |
NCT02950987 -
Screening With Whole Body MRI For Detection Of Primary Tumors In Children And Adults With Li-Fraumeni Syndrome (LFS) And Other Cancer Predisposition Syndromes
|
N/A | |
Enrolling by invitation |
NCT03176836 -
Li-Fraumeni Syndrome Imaging Study
|
N/A | |
Recruiting |
NCT01143454 -
Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System
|
||
Completed |
NCT02289326 -
Biomarker Monitoring in TP53 Mutation Carriers
|
||
Recruiting |
NCT04982744 -
Registry of Li Fraumeni and Li Fraumeni Like Syndromes
|
||
Completed |
NCT01981525 -
A Pilot Study of Metformin in Patients With a Diagnosis of Li-Fraumeni Syndrome
|
Phase 1 | |
Completed |
NCT00406445 -
Role of p53 Gene in Metabolism Regulation in Patients With Li-Fraumeni Syndrome
|
||
Recruiting |
NCT01443468 -
Clinical and Genetic Studies of Li-Fraumeni Syndrome
|
||
Completed |
NCT04966923 -
Phenotype and Prognosis of Patients With Breast Cancer and Pathogenic Variants of TP53
|
||
Recruiting |
NCT06088030 -
Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer
|
Phase 2 | |
Recruiting |
NCT03050268 -
Familial Investigations of Childhood Cancer Predisposition
|